

Michal Mark Danieli

Company name EARLY Labs Ltd. *

Website www.earlylabs.io CEO name Michal Mark Danieli

CATEGORY: Bio Convergence SESSION: Liquid biopsy & Diagnostics: Getting closer to transforming early detection and disease management

o Executive Summary EARLY Labs is developing a multi-cancer test platform (currently focusing on lung cancer) to detect cancer odor signatures (VOCs) in urine samples from its earliest stages using a patented technology combining Machine Learning and animal biosensors. Clinical and design partners include Memorial Sloan Kettering, Brigham and Women's Hospital, Mass General Hospital, Englewood Health, and top Israeli and Korean medical centers.

o Core Technology The BSP is an automatic testing platform for the binary recognition of the lung cancer VOC signature in urine samples by a machine learning algorithm based on behavioral input from trained Long-Evans rats serving as biosensors. It is the only non-invasive test with the potential to offer multi-cancer risk assessment, that can be sampled at home.

o Product Profile/Pipeline Product is in validation phase (lung cancer). A clinical study of 415 double blinded samples was performed with 93% sensitivity and 88% specificity results. A POC on the 2nd cancer type - colon cancer - is planned to be completed in Q4 2024. Partnerships forming with world leading medical centers, private screening test providers and strategic partnerships with CT manufacturers and pharma.

o Business Strategy Test to be provided as a service, operated by central EARLY laboratories, each with a volume of 650k tests per year in full capacity. Initial market entry planned in US east coast as an out-of-pocket decision support tool for CT imaging, in partner medical centers, and also as part of the portfolio of private at-home screening test providers.

What's Next? Complete validation of lung cancer test with US KOLs, including publications, Continue adding cancer types and transforming the test to a multi-cancer risk assessment test. Complete product automation and scaling support. Expand Machine Learning model to include video data input. A- fundraising round in Q4 2024 with a strategic VC to reach initial US market entry.